Elimination of Infectious Retroviruses During Preparation of Immunoglobulins

Overview

Journal Transfusion

Specialty Hematology

Date 1986 Jul 1

PMID 3014692

Citations 12

Authors

G Mitra

M F Wong

M M MOZEN

J S McDougal

J A Levy

Affiliations

Soon will be listed here.

Abstract

Safety concerns for immunoglobulin preparations have led us to study partition/inactivation of two prototype retroviruses, mouse xenotropic type C and lymphadenopathy-associated virus (LAV) of the acquired immunodeficiency syndrome (AIDS), during manufacture and storage of immunoglobulins. Reduction of infectious retrovirus titers were 10(5) to 10(8)-fold through Cohn-Oncley cold ethanol fractionation from plasma to fraction II, 10(3) to 10(5)-fold through incubation at pH 4.0 and another 10(4)-fold through incubation of the purified liquid immunoglobulin preparations at 27 degrees C or 45 degrees C. The results support the clinical and epidemiological evidence that therapeutic immunoglobulin preparations do not transmit AIDS virus.

Citing Articles

Protecting children and adults with primary antibody deficiencies against common and emergent pathogens and non-infectious complications.

Neth O, Mahlaoui N, Cunningham-Rundles C Clin Exp Immunol. 2024; 218(2):136-150.

PMID: 39011978 PMC: 11482499. DOI: 10.1093/cei/uxae059.

Safety, efficacy and pharmacokinetics of a new 10% liquid intravenous immunoglobulin (IVIG) in patients with primary immunodeficiency.

Wasserman R, Church J, Stein M, Moy J, White M, Strausbaugh S J Clin Immunol. 2012; 32(4):663-9.

PMID: 22392046 PMC: 3389237. DOI: 10.1007/s10875-012-9656-5.

Intravenous immunoglobulins: evolution of commercial IVIG preparations.

Hooper J Immunol Allergy Clin North Am. 2008; 28(4):765-78, viii.

PMID: 18940573 PMC: 7135658. DOI: 10.1016/j.iac.2008.06.002.

Pathogen inactivation and removal procedures used in the production of intravenous immunoglobulins.

Kempf C, Stucki M, Boschetti N Biologicals. 2006; 35(1):35-42.

PMID: 16581263 PMC: 7129354. DOI: 10.1016/j.biologicals.2006.01.002.

Virus safety of intravenous immunoglobulin: future challenges.

Boschetti N, Stucki M, Spath P, Kempf C Clin Rev Allergy Immunol. 2006; 29(3):333-44.

PMID: 16391410 PMC: 7090396. DOI: 10.1385/CRIAI:29:3:333.